U.S. Healthcare Services Stock News

NYSE:PRM
NYSE:PRMChemicals

Why Perimeter Solutions (PRM) Is Up 23.7% After Strong Q1 Earnings And Disciplined M&A Update

Perimeter Solutions, Inc. recently reported first-quarter 2026 results, with sales rising to US$125.07 million and net income reaching US$72.94 million, alongside higher earnings per share versus a year earlier. Management also highlighted an active mergers and acquisitions pipeline, emphasizing a repeatable “small but essential component” acquisition model that focuses on recurring revenue and operational improvement after deals close. We’ll now examine how Perimeter Solutions’ strong...
NYSE:DDS
NYSE:DDSMultiline Retail

Dividend Fortresses Three High Yields With Very Different Stories

High inflation risks, sticky interest rates and energy driven cost pressures have pushed many investors toward income they can see and touch. That is where the Dividend Fortresses screener comes in, focusing on stocks with dividend yields above 5% that aim to offer both resilience and meaningful cash payouts. Instead of trying to guess the next macro twist, you can look at companies that already return a high share of cash to shareholders. In this article you will see three stocks from the...
NYSEAM:GROY
NYSEAM:GROYMetals and Mining

Evaluating Gold Royalty (GROY) After A Profit-Making Quarter And Strong Revenue Performance

Gold Royalty (GROY) has attracted attention after reporting first quarter 2026 earnings with sales of US$7.18 million and net income of US$1.77 million, a shift from a loss in the prior year period. See our latest analysis for Gold Royalty. The share price sits at US$3.73, with a 7 day share price return of 5.97% and a 90 day share price return that is down 11.19%. The 1 year total shareholder return of 152.03% indicates strong longer term momentum despite recent volatility and follows...
NasdaqGS:BCRX
NasdaqGS:BCRXBiotechs

BioCryst’s Navenibart Deal And Pediatric Data Shape HAE Investment Case

BioCryst Pharmaceuticals (NasdaqGS:BCRX) has granted Neopharmed Gentili exclusive European licensing rights to navenibart for hereditary angioedema. The agreement includes an upfront payment and potential future milestone payments to BioCryst. Neopharmed Gentili is expected to use its existing European commercial infrastructure to support the rollout of navenibart. At ISPOR 2026, BioCryst presented real world evidence on pediatric hereditary angioedema highlighting ongoing medical and...
NYSE:PEG
NYSE:PEGIntegrated Utilities

Is Public Service Enterprise Group (PEG) Offering Value After Recent Pullback In Share Price?

If you are wondering whether Public Service Enterprise Group (PEG) stock still offers solid value at current levels, it helps to start with how its recent price and fundamentals line up. The share price closed at US$77.22, with returns that declined 2.7% over the past week and 5.0% over the past month, while sitting up 3.1% over 1 year and 47.2% over 5 years. These figures can influence how investors view both upside potential and risk. Recent news coverage has focused on PEG as a large...
NYSE:LDOS
NYSE:LDOSProfessional Services

Leidos Hypersonics Win Expands Role In High Priority Defense Programs

Leidos Holdings (NYSE:LDOS) has been awarded a U.S. Army contract worth up to $2.7b to move hypersonic weapons programs toward production. The award consolidates several advanced hypersonic efforts under a single umbrella, aimed at accelerating development and deployment. The contract supports the company’s NorthStar 2030 vision by expanding its role in high-priority national defense work. For investors watching Leidos at a share price of $124.17, this hypersonics award arrives after a...
NYSE:KVYO
NYSE:KVYOSoftware

Klaviyo Claude Integration Shifts AI To Execution As Shares Screen Undervalued

Klaviyo (NYSE:KVYO) has launched a deeper integration with Anthropic's Claude through a new Model Context Protocol connector. The update allows marketers to use natural language inside Claude to pull Klaviyo first party data, generate campaigns, and automate multi step workflows. This moves Klaviyo's AI tools from insight generation into direct execution across reporting and campaign creation. Klaviyo is rolling out this Claude integration at a time when the stock is trading at $14.24 and...